Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

atory clinical trial will be required to establish efficacy and safety of the product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose, although the timing of filing the European Phase III CTA has not yet been established. The timing of both the planned U.S. and European trials will be contingent on the timing of regulatory approvals of the trials as well as obtaining additional capital.
  • Enrollment in the ongoing Phase II clinical trial in patients with anogenital warts ("AGW") in Sweden and Germany was completed subsequent to the Company's first quarter of fiscal 2010.
  • Financing

    • Completed a private placement financing on September 8, 2009 for gross proceeds of $13,581,250.
    • Prof. Majewski, stepped down from the Board of Directors to assume the advisory role of European medical director, effective August 11, 2009.
    • Prof. Kazimierz Roszkowski-Sliz was appointed to the Board of Directors on August 17, 2009.

    FINANCIAL REVIEW

    During the first quarter of fiscal 2010, the Company recorded a loss of $3,473,000 or $0.06 per common share, resulting in a higher loss of $1,152,000 when compared to the first quarter of fiscal 2009. The Company recorded a loss of $2,321,000, or $0.05 per common share in the first quarter of fiscal 2009.

    Revenues in the first quarter of fiscal 2010 totalled $1,020,000 (2009 - $1,119,000), resulting in a decrease of $99,000 or 8.8% when compared to the first quarter of fiscal 2009.

    Product revenues totalled $903,000 in the first quarter of fiscal 2010 and represents 88.5% of total revenues. When compared to the first quarter of fiscal 2009, product revenues decreased by $18,000 or 2.0%. Sales of both Klean-Prep® and Imunovir® were marginally higher in the quarter, however these were offset by the net decrease in combined
    '/>"/>

    SOURCE Helix BioPharma Corp.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
    3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
    4. Helix BioPharma Corp. Announces Fiscal 2009 Results
    5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
    10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
    11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
    (Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
    (Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
    Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
    ... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... products from Teva Pharmaceuticals in connection with Teva,s acquisition ... own the ANDAs of fentanyl citrate lozenges, a generic ... version of Amrix®, as well as the U.S. rights ...
    ... 18, 2011 Tourists visiting the "Happiest Place on ... not able to experience it. Not all guests visiting ... walk the theme parks. Some people may appear healthy ... walking for long periods of time. Conditions stemming from ...
    Cached Medicine Technology:Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 2
    (Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
    (Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
    (Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
    (Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
    (Date:12/24/2014)... December 25, 2014 Over 700 toys, ... their local communities. That is 700 smiling little faces ... gift. Additionally over $6000 in monetary donations was given ... some of the expenses they incur through the year. ... were A Child's Haven , Shrine's Children's Hospitals, ...
    Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
    ... , PROVO, Utah , Jan. 19 ... announced that it will release fourth quarter financial results prior to the ... Hunt , president and chief executive officer, will host a conference call ... a.m. (EDT) . During the call, participants can expect to hear management ...
    ... , ANN ARBOR, Mich. , ... and MEDITECH have collaborated to offer content from the Micromedex ... Care Information System (HCIS) — Emergency Department Management, Physician Care ... one of the Micromedex clinical evidence solutions from Thomson Reuters, ...
    ... , ATLANTA , Jan. 19 ... of the Unit of Interventional Radiology at the European Institute ... 2010 Best Poster Award by Dr. Shaun Samuels , ... Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic Tumors. ...
    ... health care, particularly at the end of life, may incite ... Hopkins emeritus professor of neurology called for the start of ... month,s issue of the Journal of Medical Ethics . ... Emeritus of Pediatric Neurology and a faculty member of the ...
    ... infection, researchers find , TUESDAY, Jan. 19 (HealthDay News) -- ... treatment for sickle cell disease, a common genetic disorder, new ... in the Journal of Clinical Investigation , are based ... with the disease will benefit from treatment with statins. ...
    ... chromosome component, research shows , TUESDAY, Jan. 19 (HealthDay ... of the reasons why omega-3 fatty acids are good for ... heart disease consumed, the slower their telomeres shrank. Telomeres are ... the more times a cell divides, making them a marker ...
    Cached Medicine News:Health News:Nu Skin Enterprises to Announce Fourth Quarter and Annual 2009 Results 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Reasoning through the rationing of end-of-life care 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 3
    0.3% Yeast Extract, 0.3% Malt Extract, 0.5% Peptone, and 1.0% Glucose....
    Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
    Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
    ... units Penicillin/25,000 ug Streptomycin ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
    Medicine Products: